Single-Dose Brachytherapy Effective for Prostate Cancer

MONDAY, April 29, 2019 -- Single-dose high dose-rate (HDR) brachytherapy is safe and effective for low-risk prostate cancer, according to a study presented at ESTRO 38, the annual meeting of the European Society for Radiotherapy and Oncology, held...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8 Interventions:   Radiation: High-Dose Rate Brachytherapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Rad...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ung P Abstract PURPOSE: To report dosimetry, preliminary toxicity and health-related quality of life (HRQoL) outcomes of tumor-targeted dose-escalation delivered by integrated boost volumetric arc therapy (IB-VMAT) or MR-guided HDR brachytherapy (HDR) boost for prostate cancer. MATERIALS AND METHODS: Patients diagnosed with localized prostate cancer, with at least 1 identifiable intraprostatic lesion on multiparametric MRI (mpMRI) were enrolled in a prospective non-randomized phase II study. All patients received VMAT to the prostate alone (76 Gy in 38 fractions) plus a GTV boost: IB-VMAT (95Gy in 38 fraction...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
Radiation treatment (RT) is an effective option for men with localized prostate cancer (PCa).[1] However, local recurrences (LR) remain common in patients treated with external beam radiotherapy (EBRT) alone.[2] Dose-escalated RT to the whole gland (WG) has demonstrated increased locoregional and biochemical control in localized PCa.[3-5] A meta-analysis concluded that each 1-Gray (Gy) increased in dose delivered reduces 1.8% the risk of biochemical failure.[6] Nevertheless, concerns have been raised with regards to increased toxicity and subsequently worsening the quality of life (QoL) of patients treated with dose escalation.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
As aging is the most significant risk factor for cancer development, long-term prostate cancer (PCa) survivors have an evident risk of developing subsequent primary cancers (SPCs). Radiotherapy itself is an ad...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Conclusions: The α/β obtained in our analysis of 22.8 Gy for a range of dose per fraction between 6 and 20.5 Gy was much greater than the one currently estimated for prostate cancer using low doses per fraction. This high value of α/β explains reasonably well the data available in the region of high doses per fraction considered. PMID: 32395145 [PubMed]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
Authors: Konat-Bąska K, Chicheł A, Staszek-Szewczyk U, Maciejczyk A, Matkowski R Abstract Purpose: Prostate and colorectal cancers are the first and the third most popular malignancies in male population, in which some patients may develop these tumors metachronously or synchronously. At present, there are no standard recommendations, and oncologists need to provide an optimal management for two different cancers with an acceptable risk of possible treatment of adverse effects. Material and methods: This case report presents the treatment of a 61-year-old patient suffering from synchronous prostate and rectal...
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
To investigate long-term changes in lower urinary tract symptoms (LUTS) in patients with prostate cancer (PC) who underwent low-dose-rate brachytherapy with iodine-125 (LDR-BT).
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
ot O Abstract Often contraindicated because of the theoretical risk of progression based on the dogma of hormone dependent prostate cancer (CaP), testosterone replacement therapy (TRT) is increasingly discussed and proposed for hypogonadal patients with localized CaP. To perform a systematic literature review to determine the relationship between TRT and the risk of CaP with a focus on the impact of TRT in the setting of previous or active localized CaP. As of October 15, 2019, systematic review was performed via Medline Embase and Cochrane databases in accordance with the PRISMA guidelines. All full text articles...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
The purpose of this study was to compare an isotropic three-dimensional (3D) T2-weighted sequence sampling perfection with application-optimized contrasts by using flip angle evolution (SPACE) with an axial two-dimensional T2-weighted turbo spin echo (TSE) sequence with regard to overall image quality and the delineation of normal prostate and periprostatic anatomy for low-dose-rate prostate cancer brachytherapy planning evaluation.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Publication date: Available online 8 May 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): O. Pons-Llanas, E. Collado-Ballesteros, S. Roldan-Ortega, A. Conde-Moreno, F. Celada-Alvarez, F. Martínez-Arcelus, M.J. Pérez-Calatayud, V. Carmona-Meseguer, J. Gimeno-Olmos, V. Forner-Ferrer, A. Tormo-Micó, J. Perez-Calatayud, J. López-Torrecilla
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Pharmaceuticals | Prostate Cancer | Study